United States Patent 9,950,125 (Testosterone SC, preservative-free, single injection, powered injector): Scope, claims, and landscape
What is US 9,950,125 claiming in plain claim-scope terms?
US 9,950,125 is directed to methods of administering testosterone to a mammal where the formulation is preservative-free and the delivery is subcutaneous (SC) as a single unit dose using a powered injector (housing, chamber, needle). The claimed advantage is pharmacokinetic control: a specified plasma testosterone exposure range maintained for specified time periods (Z1/Z2/Z3), including comparisons versus an equivalent intramuscular (IM) dose at the same post-dose time point.
Core claim elements repeated across independent and dependent claims include:
- Dose/formulation: “a preservative-free composition comprising a unit dose of testosterone or a pharmaceutically acceptable ester or salt thereof in a pharmaceutically acceptable carrier”
- Route: subcutaneously to a mammal
- Delivery device: “a single injection via a powered injector comprising a housing, a chamber disposed within the housing and configured to receive the preservative-free composition, and a needle operatively associated with the chamber”
- PK target(s):
- Z1: plasma maintained between about 200 ng/dL and about 1800 ng/dL for at least 1 day (and dependents specify Z1 at least 6, 6.5, or 7 days)
- Z2: plasma maintained at a therapeutically effective level up to about 1800 ng/dL for at least 1 day
- Z3: plasma level maintained for a period after the plasma level of an equivalent IM dose drops below the SC dose at the same time point, with multiple discrete range options including “about 300 to about 1100 ng/dL” type windows or discrete anchor values
What are the independent claim anchors and how broad are they?
Claim 1 (independent): SC preservative-free unit dose + powered injector + Z1 PK window
Claim 1 requires all of the following simultaneously:
- Preservative-free composition containing unit dose testosterone (or pharmaceutically acceptable ester/salt) in an acceptable carrier
- Administered subcutaneously to a mammal
- After administration, plasma testosterone maintained between about 200 ng/dL and about 1800 ng/dL for Z1
- Z1 time period: at least 1 day
- Injection limitation: administering “consists of” a single injection via a powered injector with:
- housing
- chamber configured to receive the composition
- needle operatively associated with the chamber
Scope implications
- The preservative-free and single powered injector constraints narrow scope to specific product formats.
- The PK window in claim 1 is wide (200 to 1800 ng/dL) but the claim is still bounded by the time period Z1 (>= 1 day) and by the route + single injection device format.
Claim 10 (independent): “therapeutically effective” Z2 + single powered injector
Claim 10 has the same delivery core, but the PK element is framed as:
- Plasma testosterone maintained at a therapeutically effective level for Z2
- Z2 >= 1 day
- Upper cap framing appears indirectly via dependent/companion claims (claim 12 specifies “up to about 1800 ng/dl”)
Scope implications
- The term therapeutically effective level typically increases interpretive breadth versus a hard numeric range; however, the claim still requires the “consists of” limitation tied to SC single injection via powered injector.
- Practically, enforcement will still turn on whether measured plasma values fall within claimed “effective” criteria as supported by the specification and prosecution history.
Claim 12 (independent among your excerpt set, as written): elevated plasma up to 1800 ng/dL for Z2
Claim 12 is a method of maintaining elevated plasma levels with:
- Preservative-free SC unit dose via powered injector (single injection)
- Plasma maintained at a level up to about 1800 ng/dL for Z2 >= 1 day
Scope implications
- “Up to about 1800 ng/dl” is not the same as a band requirement; it can read as a ceiling-based limitation. Read together with other dependents (e.g., windows and discrete levels), it supports a broader strategy to capture multiple dosing/PK profiles that do not exceed the upper range.
Claim 14 (independent): dual-window + SC vs IM comparison after IM drops below SC
Claim 14 adds the most technically specific PK architecture:
- SC preservative-free unit dose via powered injector (single injection)
- Plasma maintained between about 700 ng/dl and about 1800 ng/dl for Z2
- Plasma also maintained between about 300 ng/dl and about 1100 ng/dl for Z3
- Z3 defined by a comparator event:
- “after the plasma level of an equivalent intramuscularly administered dose drops below the plasma level of the subcutaneously administered dose at the same time point post-administration”
Scope implications
- This claim is narrower and more “litigation-ready” because it includes:
- explicit numeric bands
- a defined comparator event tied to an IM arm
- It also functions as a claim-set hook to argue that the SC regimen provides a sustained elevation advantage relative to IM after a crossover point.
What dependent claims materially narrow the PK space?
Z1 narrowing (claims 5–7)
- Claim 5: Z1 at least 6 days
- Claim 6: Z1 at least 6.5 days
- Claim 7: Z1 at least 7 days
Given Z1 is already >=1 day in claim 1, these dependents progressively require longer maintenance of the 200–1800 ng/dL window.
Tight bands around the 300–1100 ng/dL range (claims 2–4; and echoed in claim 17)
- Claim 2: maintained between about 300 and about 1100 ng/dL, plus a set of overlapping sub-ranges:
- 350–1050
- 400–1000
- 450–950
- 500–900
- 550–850
- 600–800
- 650–750
- 675–725
- Claim 3: a set of discrete target values (about 300, 350, 400 … up to about 1100 ng/dL)
- Claim 4: “at least about” discrete thresholds (>= about 300, >=350 … >=1100)
Scope implications
- Claims 2 and 3 shift from broad band maintenance to specific ranges or specific levels.
- Claim 4 adds “at least about” structure, likely intended to capture profiles where measured levels stay above multiple candidate thresholds for Z1.
Liquid formulation limitation (claims 8 and 11 and 13)
- Claim 8: preservative-free composition comprises a liquid composition
- Claim 11: preservative-free composition comprises a liquid composition
- Claim 13: same
Scope implications
- Converts an already formulation-limited claim into a subtype limitation that may exclude suspensions, lyophilized formats, or non-liquid carriers, depending on specification definitions.
Single unit dose limitation (claim 9)
- Claim 9: administering consists of administering a single unit dose
Scope implications
- Reinforces the single-injection strategy even if claim 1 already indicates a unit dose; it blocks workarounds that argue multi-dose schedules or repeated injections to hit the PK window.
How does claim 14’s SC vs IM comparator mechanism expand or constrain infringement arguments?
Claim 14’s structure
Claim 14 requires two separate “maintained” windows:
- Z2: plasma 700–1800 ng/dL
- Z3: plasma 300–1100 ng/dL
- Z3 timing: “after” an IM crossover event where IM plasma drops below SC at the same time point
This creates a built-in time-relative measurement methodology for enforcement:
- Identify the timepoint where IM (equivalent dose) crosses below SC (equivalent measurement at same post-administration time).
- Then evaluate whether SC plasma stays within the Z3 band for the claimed duration after that event.
Dependent refinements to claim 14’s Z2 and Z3 levels (claims 15–18)
Z2 discrete level pairings (claim 15)
Examples listed as “selected from the group consisting of”:
- 750 and 1750
- 800 and 1700
- 850 and 1650
- 900 and 1600
- 950 and 1550
- 1000 and 1500
- 1050 and 1450
- 1100 and 1400
- 1150 and 1350
- 1200 and 1300
Z2 extended discrete group (claim 16) includes:
- 700, 750, 800, … up to 1700, 1750, 1800
(with the excerpt also showing “about 1700 mg/ml” and “about 1750 mg/ml” entries, which appear dimensionally inconsistent with the rest of the ng/dL framework as written)
Z3 discrete group (claim 17 and claim 18)
- Claim 17: Z3 is selected from ranges 350–1050, 400–1000, down to 675–725
- Claim 18: Z3 is selected from discrete values 300, 350, 400 … 1100 ng/dL
Scope implications
- These dependents are designed to capture multiple plausible PK profiles by offering a “menu” of acceptable numeric outcomes.
- They also reduce reliance on broad interpretation of “therapeutically effective level,” at least for those dependent claim combinations.
What is the technical “center of gravity” for this patent’s practical scope?
The patent’s center of gravity is the intersection of:
- Preservative-free formulation
- Subcutaneous route
- Single powered injector with housing + chamber + needle
- Sustained plasma testosterone profile, including (in claim 14) a defined SC vs IM crossover framework
In infringement mapping terms, a candidate product or regimen must align on all four dimensions to hit the broadest claims, and on multiple additional numeric constraints to hit the narrower dependents.
What does the claim set imply about design-arounds?
Even without device-specific claim construction beyond the “powered injector” components, the claim language creates high-friction boundaries:
- Preservative-free is a categorical limiter. A formulation that includes a preservative to stabilize the composition is less likely to satisfy that limitation.
- Subcutaneous + single injection is also limiting. Switching to IM, or using a multi-injection program, risks stepping outside “consists of” single injection and/or the route-specific PK comparison in claim 14.
- Powered injector is a device-structure limitation. A non-powered delivery mechanism could reduce literal coverage, depending on how “powered injector” is construed and whether the specification broadens it to specific injection mechanics.
Where does the patent sit in a likely testosterone landscape?
Without additional citation-level record data beyond the claim text you provided, the actionable positioning is still clear at the claim-theme level:
- The patent is aimed at extended SC testosterone exposure using single injection and controlled plasma ranges, rather than merely “SC testosterone exists.”
- Claim 14’s explicit IM comparator crossover indicates the patent is intended to distinguish SC sustained kinetics from IM kinetics after a timing event. That makes it likely to compete with other sustained-release SC testosterone approaches and with IM reference therapies on a “PK profile” basis.
What are the enforceable claim “tiers” to watch?
Based on the excerpt alone, there are three enforceability tiers:
-
Tier 1: Broad method claims (claim 1, claim 10, claim 12)
- Preserve the essential delivery and preservative-free constraints
- Use broad or ceiling/effective-language PK limits or wide numeric windows
-
Tier 2: PK window tightening (claims 2–7 and 17–18)
- Adds specific ranges, discrete values, and longer duration requirements
- Improves enforceability by pinning to measurable targets
-
Tier 3: SC vs IM crossover mechanistic definition (claim 14 and dependents 15–18)
- Most specific structure: defined crossover event + two-stage maintained ranges
- Most likely to be used in infringement theories that include head-to-head PK dataset narratives
Claim-by-claim scope matrix (from the excerpt)
| Claim |
Route |
Preservative-free |
Dose/format |
Injector limitation |
PK requirement |
Time definition |
| 1 |
SC |
Yes |
Unit dose |
Yes, powered injector; “consists of” |
Plasma maintained 200–1800 ng/dL |
Z1 >= 1 day |
| 2 |
SC |
Yes |
Unit dose |
Yes |
Maintained values selected (e.g., 300–1100, 350–1050 … 675–725) |
(Z1 as in claim 1) |
| 3 |
SC |
Yes |
Unit dose |
Yes |
Maintained at discrete values 300–1100 ng/dL |
(Z1 as in claim 1) |
| 4 |
SC |
Yes |
Unit dose |
Yes |
Maintained at “at least” thresholds >= 300 … >=1100 ng/dL |
(Z1 as in claim 1) |
| 5 |
SC |
Yes |
Unit dose |
Yes |
200–1800 band (as in claim 1) |
Z1 >= 6 days |
| 6 |
SC |
Yes |
Unit dose |
Yes |
200–1800 band (as in claim 1) |
Z1 >= 6.5 days |
| 7 |
SC |
Yes |
Unit dose |
Yes |
200–1800 band (as in claim 1) |
Z1 >= 7 days |
| 8 |
SC |
Yes |
Unit dose |
Yes |
Adds liquid composition |
As in claim 1 |
| 9 |
SC |
Yes |
Single unit dose |
Yes |
As in claim 1 |
As in claim 1 |
| 10 |
SC |
Yes |
Unit dose |
Yes |
“therapeutically effective” for Z2 |
Z2 >= 1 day |
| 11 |
SC |
Yes |
Unit dose |
Yes |
Adds liquid composition |
As in claim 10 |
| 12 |
SC |
Yes |
Unit dose |
Yes |
Elevated plasma up to ~1800 ng/dL for Z2 |
Z2 >= 1 day |
| 13 |
SC |
Yes |
Unit dose |
Yes |
As in claim 12, adds liquid composition |
As in claim 12 |
| 14 |
SC |
Yes |
Unit dose |
Yes |
Z2: 700–1800; Z3: 300–1100; Z3 after IM drops below SC |
Z2 and Z3 are post-event/time-window defined |
| 15 |
SC |
Yes |
Unit dose |
Yes |
Z2 at selected paired levels (e.g., 750 & 1750 … 1200 & 1300) |
Z2 tied to claim 14 |
| 16 |
SC |
Yes |
Unit dose |
Yes |
Z2 at selected discrete levels (700 … 1800, as written) |
Z2 tied to claim 14 |
| 17 |
SC |
Yes |
Unit dose |
Yes |
Z3 ranges selected (e.g., 350–1050, … 675–725) |
Z3 tied to IM crossover event |
| 18 |
SC |
Yes |
Unit dose |
Yes |
Z3 at selected discrete levels (300 … 1100) |
Z3 tied to IM crossover event |
Patent landscape: what matters most for freedom-to-operate and post-grant risk
This patent is structured to be asserted against products that:
- combine preservative-free testosterone with SC single injection and
- deliver via powered injection hardware and
- achieve a plasma profile that fits one of:
- claim 1 wide band for Z1 (or narrower Z1 dependents)
- claim 10 effective level for Z2
- claim 12 ceiling for Z2
- claim 14’s two-window method with SC vs IM crossover and its discrete/narrow dependents
In landscape terms, the competitive set is not defined solely by “SC vs IM testosterone.” It is defined by device + preservative-free format + PK-maintained ranges. A product that is SC testosterone but uses:
- preservatives,
- non-powered manual injection,
- different unit-dose schedule,
- or a PK profile outside the claimed ranges/time framework,
may reduce risk of literal coverage for these claims.
Key Takeaways
- US 9,950,125 claims methods for administering preservative-free testosterone subcutaneously as a single unit dose using a powered injector (housing + chamber + needle).
- The broadest PK anchor is claim 1’s maintenance of plasma testosterone 200–1800 ng/dL for Z1 >= 1 day; claim 10 uses “therapeutically effective” for Z2 >= 1 day; claim 12 limits to up to ~1800 ng/dL for Z2 >= 1 day.
- The narrowest and most technically specific structure is claim 14, which defines Z3 using an IM crossover event (IM drops below SC at the same post-dose time point) and requires dual maintained bands (Z2: 700–1800, Z3: 300–1100).
- Dependent claims tighten scope with longer duration thresholds (Z1 >= 6 to 7 days), discrete or narrow PK windows, and a liquid-only composition limitation.
- For infringement and landscape mapping, the differentiator is the combination of preservative-free + SC single powered injection + sustained plasma ranges, not just the drug route.
FAQs
1. What is the most infringement-sensitive claim in the excerpt?
Claim 14, because it combines dual numeric PK bands with a defined SC vs IM crossover event and additional constrained dependents (claims 15–18).
2. Can a product using an IM route avoid coverage?
Avoiding IM entirely can reduce relevance to the specific crossover framework in claim 14, but claims 1, 10, and 12 still require SC administration, so the route switch alone is a strong literal-avoidance lever for those claims.
3. Is “preservative-free” the primary formulation limiter?
Yes. Every method claim excerpted here requires a “preservative-free composition,” and dependent claims add “liquid composition” in specific claim paths.
4. What does “Z1/Z2/Z3 time period” operationally do for enforcement?
It anchors “after administration” plasma maintenance to measurable durations tied to either absolute thresholds (Z1, Z2) or an event-defined timing scheme (Z3 in claim 14).
5. Does the powered injector requirement limit infringement to specific devices?
At least to devices that meet the structural elements recited: a powered injector with a housing, chamber configured to receive the composition, and an associated needle; the “consists of” language strengthens the literal-device gating.
References
[1] United States Patent 9,950,125, claims excerpt provided by user (testosterone method; preservative-free SC unit dose; powered injector; plasma testosterone ranges and time periods Z1/Z2/Z3; SC vs IM crossover-defined Z3).
